Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Archer Aviation Inc (ACHR) vs BridgeBio Pharma Inc (BBIO) Price & Performance

Archer Aviation IncTrade
BridgeBio Pharma IncTrade

Price performance (Past 24H)

Key statistics

Archer Aviation Inc vs BridgeBio Pharma Inc — how do they compare? Archer Aviation Inc trades at $6.82 (market cap $4.78B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is far larger — about 3.5× Archer Aviation Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Archer Aviation Inc nearer its low. Which is the better fit depends on your goals.

ACHRBBIO
Market Cap
$4.78B$16.61B
Sector
IndustrialsHealth
52-Week High
$13.64$90.17
52-Week Low
$4.44$47.29
Enterprise Value
$3.12B$18.16B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Archer Aviation Inc

Archer Aviation (ACHR) trades at $5.59, up 6.88% today, with a bullish technical signal from moving averages. The company reported a Q2 2026 loss of $0.34 per share, missing estimates, but revenue trends show growth from $300,000 in 2025 to $2 million in 2026. Recent news highlights a transformative deal with Boeing to acquire Wisk Aero, Insitu, and SkyGrid, expanding into autonomous aviation and defense, which spurred a stock surge and high options trading activity.

The outlook is optimistic due to strategic expansion and strong analyst support, with 78% buy ratings and a 78.7% upside price target. However, risks include persistent losses, negative cash flow from operations, and execution challenges in scaling new businesses, requiring careful monitoring of profitability milestones.

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Archer Aviation Inc

Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.

Read more on ACHR

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO